Want to see MRNA full AI Analyst Report?
MRNA Stock Chart & Stats
$53.72
-$4.21(-8.86%)
At close: 4:00 PM EST
$53.72
-$4.21(-8.86%)
Day’s Range― - ―
52-Week Range$22.28 - $85.60
Previous CloseN/A
Volume7.58M
Average Volume (3M)8.39M
Market Cap
$24.53B
Enterprise Value$16.16K
Total Cash (Recent Filing)$5.21B
Total Debt (Recent Filing)$1.30B
Price to Earnings (P/E)―
Beta1.23
Next Earnings
Jul 31, 2026EPS Estimate
-2.04Next Dividend Ex-DateN/A
Dividend YieldN/A
Share Statistics
EPS (TTM)-8.15
Shares Outstanding396,786,250
10 Day Avg. Volume7,399,852
30 Day Avg. Volume8,392,437
Financial Highlights & Ratios
PEG Ratio0.19
Price to Book (P/B)1.33
Price to Sales (P/S)5.90
P/FCF Ratio-5.56
Enterprise Value/Market Cap<0.01
Enterprise Value/Revenue<0.01
Enterprise Value/Gross Profit>-0.01
Enterprise Value/Ebitda>-0.01
Forecast
1Y Price Target
$46.64Price Target Upside-13.18% Downside
Rating ConsensusHold
Number of Analyst Covering16
EPS Forecast (FY)-8.67
Revenue Forecast (FY)$2.09B
Bulls Say, Bears Say
Bulls Say
Strong Balance Sheet, Low LeverageModerna's low leverage and sizable equity position provide durable financial flexibility to fund R&D, regulatory filings, and manufacturing scale. This balance sheet strength helps absorb near-term cash drawdowns and supports strategic partnerships and investments over the next 2–6 months.
Regulatory Approvals Expanding Product BaseNew approvals (mNEXSPIKE and flu+COVID combo) and an expanding infectious-disease portfolio materially diversify Moderna's revenue beyond Spikevax. Durable regulatory wins increase commercial optionality and long-term addressable market for respiratory vaccines across geographies.
Meaningful Cost Reductions And DisciplineSustained cost discipline and a 26% YoY reduction in adjusted cash costs signal improved operating leverage potential. If maintained, lower cash costs reduce burn, extend runway, and increase the probability that R&D and commercialization can proceed without immediate external financing.
Bears Say
Sustained Negative Cash GenerationPersistent negative operating and free cash flow reflect a structural cash burn that erodes liquidity over time. Continued deficits constrain capital allocation, force drawdown of reserves, and raise the likelihood the company must slow projects or seek financing if revenue or margin trends don't improve.
Large Litigation Charge Plus Contingent ExposureA near-term $950M settlement (with $878M recognized) and potential additional liability up to $1.3B are structural cash and cost-of-sales shocks. This reduces operating flexibility, increases earnings volatility, and creates multi-year legal uncertainty that can divert capital from R&D and commercialization.
Profitability Still Deeply NegativeNegative gross margins and deeply negative operating margins indicate the current cost structure exceeds revenue capacity. Until margins sustainably normalize, losses will erode equity, limit self-funding of development programs, and increase reliance on cash reserves or external funding.
Moderna News
MRNA FAQ
What was Moderna’s price range in the past 12 months?
Moderna lowest stock price was $22.28 and its highest was $85.60 in the past 12 months.
What is Moderna’s market cap?
Moderna’s market cap is $24.53B.
When is Moderna’s upcoming earnings report date?
Moderna’s upcoming earnings report date is Jul 31, 2026 which is in 11 days.
How were Moderna’s earnings last quarter?
Moderna released its earnings results on May 01, 2026. The company reported -$3.4 earnings per share for the quarter, beating the consensus estimate of -$4.446 by $1.046.
Is Moderna overvalued?
According to Wall Street analysts Moderna’s price is currently Overvalued.
Does Moderna pay dividends?
Moderna does not currently pay dividends.
What is Moderna’s EPS estimate?
Moderna’s EPS estimate is -2.04.
How many shares outstanding does Moderna have?
Moderna has 396,786,250 shares outstanding.
What happened to Moderna’s price movement after its last earnings report?
Moderna reported an EPS of -$3.4 in its last earnings report, beating expectations of -$4.446. Following the earnings report the stock price went down -1.241%.
Which hedge fund is a major shareholder of Moderna?
Currently, no hedge funds are holding shares in MRNA
What is the TipRanks Smart Score and how is it calculated?
Smart Score combines eight research factors - such as analyst recommendations, hedge fund trends, and technical indicators - to measure a stock’s outlook. These signals are unified into a single score that reflects bullish or bearish momentum. See detailed methodology
Moderna Stock Smart Score
Neutral
1
2
3
4
5
6
7
8
9
10
Analyst Consensus
Hold
Average Price Target:
$46.64 (-13.18% Downside)
$46.64 (-13.18% Downside)
Blogger Sentiment
Bullish
MRNA Sentiment 70%
Sector Average 66%
Sector Average 66%
Hedge Fund Trend
Decreased
By 178.1K Shares
Last Quarter.
Last Quarter.
Insider Transactions
Sold Shares
Worth $433.9K over
the Last 3 Months
the Last 3 Months
Crowd Wisdom
Very Positive
Last 7 Days ▲ 0.9%
Last 30 Days ▲ 11.9%
Last 30 Days ▲ 11.9%
News Sentiment
Very Bearish
Bullish news 0%
Bearish news 100%
Bearish news 100%
Technicals
SMA
Positive
20 days / 200 days
Momentum
91.98%
12-Months-Change
Fundamentals
Return on Equity
-36.73%
Trailing 12-Months
Asset Growth
-9.57%
Trailing 12-Months
Company Description
Moderna
Moderna, Inc., a biotechnology firm, is dedicated to the discovery, development, and commercialization of messenger RNA (mRNA) based therapies and preventive medicines. Its extensive research and development efforts target a broad spectrum of medical needs, including infectious diseases, cancer immunology, rare conditions, cardiovascular ailments, and autoimmune disorders, with operations spanning the United States, Europe, and other global markets. The company's diverse product pipeline encompasses various vaccine candidates: those for respiratory illnesses like COVID-19, influenza, and respiratory syncytial virus (RSV); latent viral infections such as cytomegalovirus (CMV), Epstein-Barr virus (EBV), human immunodeficiency virus (HIV), herpes simplex virus (HSV), and varicella-zoster virus (VZV); and public health threats like Zika and Nipah. Additionally, Moderna is advancing systemic secreted and cell surface-targeted therapeutics, an array of cancer vaccines (including personalized, KRAS, and checkpoint varieties), intratumoral immuno-oncology products, localized regenerative treatments, systemic intracellular medicines, and inhaled pulmonary solutions. Moderna maintains strategic alliances with several prominent entities, including AstraZeneca PLC, Merck & Co., Inc., Vertex Pharmaceuticals Incorporated, Vertex Pharmaceuticals (Europe) Limited, Carisma Therapeutics, Inc., Metagenomi, Inc., the Defense Advanced Research Projects Agency (DARPA), the Biomedical Advanced Research and Development Authority (BARDA), the Institute for Life Changing Medicines, and The Bill & Melinda Gates Foundation. It also holds a collaboration and license agreement with Chiesi Farmaceutici S.P.A. Founded in 2010 as Moderna Therapeutics, Inc., the company officially became Moderna, Inc. in August 2018. Its corporate headquarters are located in Cambridge, Massachusetts.
MRNA Revenue Breakdown
61.68% U.S.
2.73% Europe
35.60% Rest of World
MRNA Stock 12 Month Forecast
Average Price Target
$46.64
▼(-13.18% Downside)
Technical Analysis
Ionis Pharmaceuticals
―
Protagonist Therapeutics
―
Rhythm Pharmaceuticals
―
Revolution Medicines
―
―
Ownership Overview
7.74% Insiders
28.21% Mutual Funds
0.11% Other Institutional Investors
40.30% Public Companies and Individual Investors